Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tal Etan"'
Autor:
Hagai Ligumsky, Herut Dor, Tal Etan, Inbal Golomb, Alla Nikolaevski-Berlin, Inbal Greenberg, Tamar Halperin, Yoel Angel, Oryan Henig, Avishay Spitzer, Marina Slobodkin, Ido Wolf
Publikováno v:
The Lancet. Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a03d3a3c3a8437d494d28b9ca92705a
https://pubmed.ncbi.nlm.nih.gov/34953523
https://pubmed.ncbi.nlm.nih.gov/34953523
Autor:
Lior Galazan, Nadir Arber, Manuel Waller, Esraa Safadi, Assaf Croll, Tami Halperin, Noam Vaknin, Inbal Greenberg, Alla Nikolaevski-Berlin, Tal Etan, Hagai Ligumsky, Ido Wolf, Asaf Wasserman
Publikováno v:
JNCI Journal of the National Cancer Institute
J Natl Cancer Inst
J Natl Cancer Inst
BackgroundActivity and safety of the SARS-CoV-2 BNT162b2 vaccine in actively treated patients with solid tumors is currently unknown.MethodsWe conducted a retrospective study of 326 patients with solid tumors treated with anticancer medications to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e2f6803664a6e390e587589c795b288
http://europepmc.org/articles/PMC8499747
http://europepmc.org/articles/PMC8499747
Autor:
Rinat Yerushalmi, Adriana Tibau, Tal Etan, Hadar Goldvaser, Daniel Shepshelovich, Eitan Amir, Assaf Moore
Publikováno v:
Cancer Research. 81:PS14-13
Background: NCCN guidelines include recommendations not approved by the FDA. We aimed to compare the NCCN recommendations for metastatic breast cancer (MBC) with the FDA approved indications and to identify characteristics that are associated with NC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1809d7adbdcba3f866920cd5f4a7bb3d
https://doi.org/10.1158/1538-7445.sabcs20-ps14-13
https://doi.org/10.1158/1538-7445.sabcs20-ps14-13
Autor:
Tal Etan, Rinat Yerushalmi, Ariadna Tibau, Eitan Amir, Daniel Shepshelovich, Hadar Goldvaser, Assaf Moore
Publikováno v:
Cancer Treatment Reviews. 91:102113
National Comprehensive Cancer Network (NCCN) guidelines can include recommendations for off-label use of anti-cancer drugs. Here, we evaluate NCCN recommendations not supported by US Food and Drug Administration (FDA) approval and explore association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee02167b179b5b15ea6f71baed04761
https://doi.org/10.1016/j.ctrv.2020.102113
https://doi.org/10.1016/j.ctrv.2020.102113
Autor:
Tammi Rubinstein, Chen Varol, Gilad W. Vainer, Ehud Zigmond, Gil Har-Zahav, Tal Etan, Nir Skalka, Iris Barshack, Rina Rosin-Arbesfeld, Keren Merenbakh-Lamin, Shiri Shahmoon, Metsada Pasmanik-Chor, Tami Rubinek, Ido Wolf
Publikováno v:
Oncogene. 38(6)
Klotho is an anti-aging transmembrane protein, which can be shed and function as a hormone. Accumulating data indicate klotho as a tumor suppressor in a wide array of malignancies and indicate the subdomain KL1 as the active region of the protein. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62525922d5194febd82f5b27a8f28088
https://pubmed.ncbi.nlm.nih.gov/30232408
https://pubmed.ncbi.nlm.nih.gov/30232408
Autor:
Chen Varol, Tal Etan, Tammi Rubinstein, Tami Rubinek, Ido Wolf, Shiri Shahmoon, Rina Rosin-Arbesfeld, Iris Barshack, Ehud Zigmond
Publikováno v:
Cancer Research. 77:4507-4507
Klotho is a transmembrane protein, which can be shed and act as a circulating hormone. Klotho-deficient mice manifest a syndrome resembling accelerated aging, while klotho overexpression extends life span. We previously identified klotho as a breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::948cf02e0001645fa3a46074da4d8c18
https://doi.org/10.1158/1538-7445.am2017-4507
https://doi.org/10.1158/1538-7445.am2017-4507
Autor:
Ido Wolf, Metsada Pasmanik-Chor, Nir Skalka, Tammi Rubinstein, Rina Arbesfeld, Shiri Shahmoon, Gil Har Zahav, Tami Rubinek, Tal Etan
Publikováno v:
Cancer Research. 75:4959-4959
Aberrant activation of the canonical Wnt signal transduction pathway is implicated in the development and progression of colorectal cancer (CC). The key effector protein of this pathway is β-catenin, which functions with T-cell factor/lymphoid enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47344127c3116cd3f6f0ddf231a8e62d
https://doi.org/10.1158/1538-7445.am2015-4959
https://doi.org/10.1158/1538-7445.am2015-4959